Attention deficit hyperactivity disorder: Diagnosis and drug therapy;Diagnóstico y tratamiento farmacológico del trastorno por déficit de atención e hiperactividad

Medicina Clinica

Volumn 120, Issue 6, 2003, Pages 222-226

  Esperón, César Soutullo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

ADHD; Atomoxetine; Bupropion; Clonidine; Methylphenidate; Stimulants; Tricyclics

Indexed keywords

ADDERAL; AMFEBUTAMONE; AMPHETAMINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; IMIPRAMINE; METHYLPHENIDATE; MODAFINIL; PEMOLINE MAGNESIUM; QUOMEN; RUBIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZYNTABAC;

ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG FORMULATION; EUROPE; GROUP THERAPY; HUMAN; MALE; PREVALENCE; PSYCHOTHERAPY; REVIEW; SPAIN; SYMPTOMATOLOGY;

EID: 0037460439     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13043316     Document Type: Review

References (67)

1. American Academy of Pediatrics, Committee on Quality Improvement and Subcommittee on ADHD. Clinical practice guideline: diagnosis and evaluation of the child with ADHD. Pediatrics 2000;105:1158-70.
2. Hechtman L. Assesment and diagnosis of ADHD. Child Adolesc Clin North Am 2000;9:481-98.
3. Brown RT, Borden KA. Hyperactivity at adolescence: some misconceptions and new directions. J Clin Child Psychol 1986;15:194-209.
4. Klein RG, Mannuzza S. Long-term outcome of hyperactive children: a review. J Am Acad Child Adolesc Psychiatry 1992;30:383-7.
5. Leibson CL, Katusic SK, Barbaresi WJ, Ranson J, O'Brien PC. Use and costs of medical care for children and adolescents with and without ADHD. JAMA 2001;285:60-6.
6. Cantwel DP. Attention deficit disorder. A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996;35:978-87.
7. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biological Psychiatry 1999;46:1234-42.
8. Thapar A, Holmes J, Poulton K, Harrington R. Genetic basis of attention deficit hyperactivity. Br J Psychiatry 1999;174:105-11.
9. World Health Organization. The Tenth Revision of the International Clasification of Diseases and Related Health Problems (ICD-10). Geneve: WHO, 1992.
10. Diagnostic and statistical manual of mental disorders. 4.th ed. DSM-IV. Washington, DC: APA, 1994.
11. Narbona-García J, Sánchez-Carpintero R. Neurobiología del trastorno de la atención e hipercinesia en el niño. Rev Neurol 1999;28(Suppl 2): 160-4.
12. Narbona J. Alta prevalencia del TDAH: ¿niños trastornados o sociecad maltrecha? Rev Neurol 2001;32:229-31.
13. Schweitzer JB, Cummins TK, Kant CA. Attention-deficit/hyperactivity disorder. Med Clin North Am 2001;85:755-77.
14. Benjumea Pino P, Mojarro Práxedes MD. Trastornos hipercinéticos: estudio epidemiológico en doble fase de una población sevillana. An Psiquiatría 1993;9:306-11.
15. Farré A, Narbona J. Índice de hipercinesia y rendimiento escolar. Validación del cuestionario de Conners en nuestro medic. Acta Pediatr Esp 1989;47:103-9.
16. Gómez-Beneyto M, Bonet A, Catalá MA, Puche E, Vila V. Prevalence of mental disorders among children in Valencia, Spain. Acta Psichiatr Scand 1994;89:352-7.
17. Andrés MA, Catalá MA, Gómez-Beneyto M. Prevalence, comorbidity, risk factors and service utilisation of disruptive behaviour disorders in a community sample of children in Valencia (Spain). Soc Psychiatry Psychiatr Epidemiol 1999;34:175-9.
18. Andrés-Carrasco MA, Catalá MA, Gómez-Beneyto M. Estudio de la prevalencia del TDAH en niños de 10 años residentes en el municipio de Valencia. Actas Luso-Esp Neurol Psiquiatr 1995;23:184-8.
19. Curran S, Taylor EA. Attention-deficit hyperactivity disorder: biological causes and treatments. Curr Opin Psychiatry 2000;13:397-402.
20. Conners CK: Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Ped Clin North Am 1999;46:857-70.
21. Rubia K, Smith A. Attention deficit hyperactivity disorder: current findings and treatment. Curr Opin Psychiatry 2001;14:309-16.
22. Cabanyes Truffino J, Polaino-Lorente A. Perspectivas neurobiológicas del déficit de atención con hiperactividad. Med Clin (Barc) 1992;98:591-4.
23. Wender PH, Reimherr FW. Bupropion treatment of ADHD in adults. Am J Psychiatry 1990; 147:1018-20.
24. Wilens TB, Biederman J, Abrantes AM, Spencer TJ. A naturalistic assesment of protriptyline for ADHD. J Am Acad Child Adolesc Psychiatry 1996;35:1485-90.
25. Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with ADHD. J Fam Pract 1999;48:15-20.
26. Spencer T, Biederman J, Wilens T, Steingard R, Geist D. Nortriptyline treatment of children with ADHD and the disorder of Tourette's syndrome. J Am Acad Child Adoesc Psychiatry 1993;32:206-10.
27. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T. Nortriptilyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 1993;32:343-9.
28. Wilens TE, Biederman J, Spencer T, Geist DE. A retrospective study of serum levels and ECG effects of nortriptyline in children and adolescents. J Am Acad Child Adolesc Psychiatry 1993;33:270-7.
29. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for ADHD. Arch Gen Psychiatry 1999;56:1073-86.
30. MTA Cooperative Group. Moderators and mediators of treatment response for children with ADHD. Arch Gen Psychiatry 1999;56:1088-96.
31. Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Am Acad Child Adolesc Psychiatry 2001;40:188-96.
32. Keating GM, McClellan K, Jarvis B. Methyphenidate (OROS® Formulation). CNS Drugs 2001;15:495-500.
33. Robb AS, Stein MA. Parent preference for OROS MPH qd over MPH tid. Actas de American Psychiatric Association Annual Meeting, NR 335. Philadelphia, PA, mayo 2002.
34. Wigal S, Swanson JM, Lerner M. Comparison of duration of effect of OROS MPH with MPH tid in ADHD children. Actas de American Psychiatric Association Annual Meeting, NR 84. New Orleans, LA, mayo 2001.
35. Schnipper E. Efficacy of OROS MPH in adolescents with ADHD in a community setting. Actas de American Psychiatric Association Annual Meeting, NR 735. New Orleans, LA, mayo 2001.
36. Greenhill LL. Efficacy and safety on once-daily methylphenidate HCI, standard methylphenidate and placebo in children with ADHD. Actas de American Psychiatric Association Annual Meeting, NR 667. Chicago, IL, mayo 2000.
37. American Academy of Child and Adolescent Psychiatry. Practice parameters for the use of stimulant medication in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41: 26S-49S.
38. Biederman J, Quinn D, Weiss M, Wigal M, Markabi S, Weidenman M, et al. Methylphenidate hydrochloride extender-releas capsules (Ritalin-LA): a new once a day therapy for ADHD. Actas de American Psychiatric Association Annual Meeting, NR 334. Philadelphia, PA, mayo 2002.
39. Conners CK, Casant C, Elia J, Covey D, Telew N, Zeldis J, et al. Randomized trial of d-MPH Focalin and d,1-MPH in children with ADHD. Actas de American Psychiatric Association Annual Meeting, NR 345. Philadelphia, PA, mayo 2002.
40. West SA, Johnson D, Wigal S, Zeldis J. Withdrawal trial of dex-methylphenidate HCI Focalin in children with ADHD. Actas de American Psychiatric Association Annual Meeting, NR 341. Philadelphia, PA, mayo 2002.
41. Rugino TA, Copley TC. Effects of modafinil in children with ADHD: an open-label study. J Am Acad Child Adolesc Psychiatry 2001;40:230-5.
42. Rugino TA, Samsock TC, Adkins L. Modafinil in children with ADHD: a double-blind, placebo controlled study. Actas de American Psychiatric Association Anual Meeting, n.o 77. Philadelphia, PA, mayo 2002.
43. Taylor FB. Comparing modafinil to dextroamphetamine in the treatment of ADHD. American Psychiatric Association Anual Meeting NR 657. Chicago, IL, mayo 2000.
44. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, et al. A controlled clinical trial of bupropion for ADHD in adults. Am J Psychiatry 2001;158:282-8.
45. Spencer T, Biederman J, Wilens T, Harding M, O'Donell D, Griffin S. Pharmacotherapy of ADHD across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-32.
46. Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of bupropion in children with ADHD. Psychopharma 1987;23:120-2.
47. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, et al. Bupropion HCI in ADHD. J Am Acad Child Adolesc Psychiatry 1996; 35:1314-21.
48. Barrickman L, Perry P, Allen A, Kuperman S, Arndt S, Herrmann K, et al. Bupropion vs methylphenidate in the treatment of ADHD. J Am Acad Child Adolesc Psychiatry 1995;34:349-57.
49. Wender PH, Reimherr FW. Bupropion treatment of ADHD in adults. Am J Psychiatry 1990;147:1018-20.
50. Biederman J, Spencer T. Non-stimulant treatments for ADHD. European Child & Adolesc Psychiatry 2000b;9:151-9.
51. Rube D. Attention-deficit hyperactivity disorder. En: Klykylo WM, Kay J, Rube D, editors. Clinical child psychiatry. Philadelphia: W.B. Saunders Company, 1998.
52. Green WH. Child and adolescent clinical psychopharmacology. 2.nd ed. Baltimore: Williams & Wilkins, 1995.
53. Physician's drug handbook. 6th ed. Springhouse: Springhouse Corp., 1995; p. 127.
54. Biederman L, Baldessarini R, Goldblatt A, Lapey K, Doyle A, Hesslin P. A naturalistic study of 24-hour electrocardiographyic recordings and echocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adoles Psychiatry 1993;32:805-13.
55. Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child and Family Psychology Review 2000;3;243-67.
56. American Academy of Child and Adolescent Psychiatry Official Action. Practice parameters for the assessment and treatment of children, adolescents and adults with ADHD. J Am Acad Child Adolesc Psychiatry 1997;36(Suppl 10):85-121.
57. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, et al. Atomoxetine and methilphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psyychiatry 2002;41:776-84.
58. Heiligenstein J, Spencer T, Faries DE, Biederman J, Kratochvil CJ, Conners CK. Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD. Actas de Scientific Proceedings of the 47th Annual Meeting of the American Accademy of Child and Adolescent Psychiatry. New York, Octubre 2000.
59. Michelson D, Wernicke J, Heiligenstein J, Allen AJ, Faries D, Spencer T, et al. Efficacy of LY139603 (tomoxetine), a non-dopaminergic intervention for ADHD. Biol Psychiatry 2001;49:15S.
60. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al, and the atomoxetine ADHD Study group. Atomoxetine in the treatment of children and adolescents with ADHD: a randomized placebo-controlled, dose-response study. Pediatrics 2001;108:E83-91. Disponible en: www.pediatrics.org/cgi/content/full/108/5/e83
61. Allen AJ, Spencer TJ, Heiligenstein JH, Faries DE, Kelsey DK, Laws HF, et al. Safety and efficacy of tomoxetine for ADHD in two double-blind, placebo-controlled trials. Biol Psychiatry 2001;49:32S.
62. Allen AJ, Michelson D, Harder DR, Trapp NJ, Kelsey DK. Efficacy of atomoxetine in children and adolescents with ADHD. Actas de American Psychiatric Association Annual Meeting, NR 348. Phipladelphia, PA, mayo 2002.
63. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. Effectiveness and tolerability of tomoxetine in adults with ADHD. Am J Psychiatry 1998;155:693-5.
64. Wernicke JF, Allen AJ, Faries D, Heiligenstein JH, Kelsey D, Kendrick K, et al. Safety of tomoxetine in clinical trials. Biol Psychiatry 2001;49: 159S.
65. Wernicke JF, Allen AJ, Faries D, Heiligenstein JH, Kelsey D, Kendrick K, et al. Long-term safety of atomoxetine in children and adolescents with ADHD. Actas de American Psychiatric Association Annal Meeting, NR 338. Philadelphia, PA, mayo 2002.
66. Witcher JW, Kurtz DL, Sauer JM, Michelson D, Smith BP, Ruff DD. Pharmacokinetic/dynamic relationship of atomoxetine exposure and efficacy. Actas de American Psychiatric Association Annal Meeting, NR 450. Philadelphia, PA, mayo 2002.
67. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with conduct disorders. J Am Acad Child Adoles Psychiatry 1997;36: 122S-39S.